Paget's disease in an Omani: long-term improvement following a single injection of Zoledronic acid.
Paget's disease is often discovered in asymptomatic patients either as an incidental finding of raised ALP or on X-rays taken for an unrelated problem. (8) It may remain undiagnosed for several years in countries where the disease is uncommon. Symptomatic disease is rare, but in some patients, several serious complications may occur. These include bone pain, deformity, fractures, immobilization hypercalcemia, neurological compression syndromes, osteosarcoma, and high output congestive failure when the skeleton is extensively involved. (3,6)
Bisphosphonate therapy is now the most commonly used treatment for Paget's disease, often normalizing biochemical markers of the bone turnover for prolonged periods. (9) Here we report the case of a 66-year-old patient who responded dramatically to treatment with calcitonin followed by a single injection of zoledronic acid.
A 66-year-old Omani male presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of progressive skull enlargement [Figure 1], bone pain, left-sided deafness, tinnitus, and unsteadiness of gait. He had undergone coronary artery bypass surgery successfully seven months prior. He was taking simvastatin, aspirin, and valsartan. A magnetic resonance imaging (MRI) brain scan was obtained three months earlier to exclude the possibility of a space-occupying lesion. His physical examination revealed enlargement of the skull and sensory neural deafness in his left ear. The investigations showed normal bone, electrolytes, and liver profiles (calcium 2.3 mmol/L, phosphate 1.3 mmol/L, creatinine 80 mmol/L, albumin 48 g/L, aspartate aminotransferase (AST) 25 U/L, and alanine aminotransferase (ALT) 21 U/L). However, he had grossly elevated serum ALP (1500 IU/L; normal range 45-100) and bone formation and resorption markers osteocalcin (139 UG/L; normal range 13-25) and urinary deoxypyridinoline/ creatinine (63 nmol/L; normal range 2.3-5.4). The skull X-ray showed thick bones and the "cotton wool" spots that characterize the osteoblast response [Figure 1]. The bone scan showed the involvement of skull, ribs, cervical spine, and tibia with an isotopic skull:femoral ratio of 34% [Figure 2]. The clinical, biochemical, and radiological findings were diagnostic of active Paget's disease. The patient was unaware of any similarly affected family member.
Initially, we started him on subcutaneous calcitonin daily for six months. During this time his bone pain improved, and there was a small fall in ALP levels. This was followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a gradual reduction of serum ALP from 1500 U/L to 112 U/L [Figure 3], and normalization of osteocalcin and urinary deoxypyridinoline levels [Table 1] over an 18 month period with a considerable improvement in his clinical symptoms. There was a reduction in head size, indicated by the size of his Kuma (an Omani hat). A repeat bone scan revealed a marked reduction of the skull:femur ratio from 34% to 4% [Figure 4]. Currently, his response to treatment is being monitored with serial ALP measurement. If these increase, a further infusion of zoledronic acid will be given. He was also given calcium and vitamin D3 two weeks before starting treatment to exclude the possibility of associated vitamin D deficiency osteomalacia.
Paget's disease of bone is a localized bone remodeling disorder of uncertain etiology, (10) although environmental and genetic factors are thought to be involved. In the UK, mutations of the sequestosome 1 gene (SQSTM1) are found in approximately 11% of affected individuals. Patients with mutations present at an earlier age and have more affected bones than those without mutations. Currently, the American Society for Bone and Mineral Research do not recommend routine genetic testing. (11) Paget's disease is not new and was found in 1000-year-old Anglo-Saxon skeletal remains. (12) Both men and women are affected with slight male preponderance. The bone that is remodeled by this pathological process becomes enlarged and mechanically weakened. A stretched periosteum produces bone pain by enlargement of the bone or by increased pressure on the medulla due to increased blood flow in the diseased bone. (3) This bone expansion will cause skeletal deformity, fractures, and various neurological compression syndromes. However, most patients with Paget's disease are asymptomatic and discovered because of increased serum ALP or as an incidental X-ray finding. (13)
This disorder is most unusual in the Arab world, (4,5) which explains why the diagnosis is often delayed. Affected individuals are often thought to have bone tumors or osteomyelitis. We elected to treat this patient due to the presence of the following: bone pain, extensive skull involvement, tinnitus, and unsteadiness of gait. Prophylactic treatment may be indicated in several situations including preparation for orthopedic procedures and vertebral body involvement to prevent neurologic compression syndromes. (14)
The patient was started on calcitonin initially as this drug directly inhibits osteoclast activity and reduces bone pain, which is possibly due to the fall in bone blood flow. (15,16) Using calcitonin for three to six months before giving the patient bisphosphonate will allow bone remodeling and normal lamellar bone formation. (17,18)
A good example of this was seen in a treated Saudi Bedouin patient, where healing of the V-shaped bony defects and the cortical bone remodeling during treatment with calcitonin occurred. (4) The use of bisphosphonates alone can produce healing of lytic lesions on radiographs, but they do not induce bone remodeling. (19)
Calcitonin treatment is infrequently used in the management of Paget's disease. However, our experience indicates that it will improve bone remodeling with obvious radiological improvement in juvenile (20) and adult Paget's disease. (4) Furthermore, normal lamellar bone is laid down during treatment. (18) For this reason, we usually give a short course of calcitonin before starting bisphosphonate treatment particularly when affected areas of the bone are likely to cause problems and need strengthening.
After six months of calcitonin treatment to achieve cortical bone healing, the patient received a 5 mg intravenous infusion of zoledronic acid. There was further progressive clinical and biochemical improvement and after one year his serum ALP and bone turnover markers became normal. This effect has persisted for 3 years, to date. Zoledronic acid was chosen as it proved to be more effective in Paget's disease than the other available bisphosphonates. (19)
Patients with Paget's disease requiring treatment should receive calcitonin initially to reduce bone turnover and allow normal bone remodeling before starting treatment with a bisphosphonate.
Received: 20 November 2014
Accepted: 14 February 2015
The authors declared no conflicts of interest.
(1.) Paget J. On a form of chronic inflammation of bones. Med Chir Trans 1877; 60:37-63.9.
(2.) Schmorl G. Uber Osteitus deformans Paget. Virchow's Archiv fur pathologische Anatomie und Physiologie 1932; 283:694.
(3.) Woodhouse NJY. Paget's disease. Clinics in Rheumatology Disease 1981 Dec; 7:3.
(4.) Woodhouse NJY, El-baage T. Paget's disease in a Bedouin. Successful Management with calcitonin and sodium Etidronate. Saudi Med J 1988; 9(1):78-82.
(5.) Alshaikh OM, Almanea H, Alzahrani AS. Paget disease of the bone: does it exist in Saudi Arabia? Ann Saudi Med 2011 May-Jun; 31(3):305-310.
(6.) Howarth S. Cardiac output in osteitis deformans. Clin Sci 1953; 12(3):271-275.
(7.) Barry HC. Fractures of the femur in Paget's disease of bone in Australia. J Bone Joint Surg Am 1967 Oct; 49(7):1359-1370.
(8.) Melmed S, Polonsky KS, Larseen RP, Kronenberg HM. Williams Textbook of Endocrinolog. 12th ed. Philadelphia: Saunders Elsevier; 2011.
(9.) Reid IR, Nicholson GC. Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996 Oct; 101(4):341-348.
(10.) Siris ES, Roodman GD. Paget's disease of bone. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. p. 320-330.
(11.) Rios M, Langston AL, Alonso N, Goodman K, Selby PL, Fraser WD, et al, Mutation of SQSTM1 are associated with severity and clinical outcome in Paget's disease of bone. J Bone Miner Res 2010 Nov; 25(11):2368-2373.
(12.) Wells C, Woodhouse N. Paget's disease in an Anglo-Saxon. Med Hist 1975 Oct; 19(4):396-400.
(13.) Altman RD. Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum 1980 Oct; 23(10):1121-1127.
(14.) Woodhouse NJ. The clinical applications of calcitonin. Br J Hosp Med 1974 May; 2:677-684.
(15.) Woodhouse NJ. Paget's disease of bone; complications and treatment in Modern Topics in Rheumatology. In: Hughes GRV editor. Heinemann Medical. London; 1976. p. 187
(16.) Woodhouse NJ, Crosbie WA, Mohamedally SM. Cardiac output in Paget's disease: response to long-term salmon calcitonin therapy. Br Med J 1975 Dec; 4(5998):686-688.
(17.) Woodhouse NJ, Joplin GF, MacIntyre I, Doyle FH. Radiological regression in Paget's disease treated by human calcitonin. Lancet 1972 Nov; 2(7785):992-994.
(18.) Bordier P, Woodhouse NH, Joplin GF, Tunchot S. Quantitative bone histology in Paget's disease. J Bone Joint Surg Br 1972; 54:553-554.
(19.) Matthews BG, Naot D, Bava U, Callon KE, Pitto RP, McCowan SA, et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009 Feb; 94(2):691-694.
(20.) Doyle FH, Woodhouse NJ, Glen AC, Joplin GF, MacIntyre I. Healing of the bones in juvenile Paget s disease treated by human calcitonin. Br J Radiol 1974 Jan; 47(553):9-15.
Omayma Elshafie  *, Nooralddin Alsaffi , Samir Hussain  and Nicholas Woodhouse 
 Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman
 Department of Radiology, Sultan Qaboos University Hospital, Muscat, Oman
* Corresponding author: [mail] firstname.lastname@example.org
Table 1: Osteocalcin and urinary deoxypyridinoline levels before and after treatment. Treatment Osteocalcin Urinary deoxypyridinoline Before 139 63 After 28 5 Urinary deoxypyridinoline/creatinine normal range 2.3/5.4 nmol/L Osteocalcin normal range 13/25 UG/L Figure 3: Response of ALP to calcitonin and zoledronic acid injections. Alkaline phosphatase U/L Months 0 3 6 9 12 15 18 Calcitonin 15000 1400 1345 Aclasta 1345 500 215 170 125 Alkaline 80 80 80 80 80 80 80 Phosphatase (normal range) Note: Table made from line graph.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CASE REPORT'|
|Author:||Elshafie, Omayma; Alsaffi, Nooralddin; Hussain, Samir; Woodhouse, Nicholas|
|Publication:||Oman Medical Journal|
|Article Type:||Case study|
|Date:||Mar 1, 2016|
|Previous Article:||The accuracy of IOS device-based uHear as a screening tool for hearing loss: a preliminary study from the Middle East.|
|Next Article:||Acute measles encephalitis in an immigrant syrian child: case report and review of the literature.|